NCT04008355View on ClinicalTrials.gov

A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 22, 2020

Primary Completion Date

July 18, 2022

Study Completion Date

September 30, 2024

Conditions
Progressive Supranuclear Palsy
Interventions
DRUG

AZP2006 oral solution

Once daily intake in the morning

DRUG

Placebo oral solution

Once daily intake in the morning

Trial Locations (3)

59037

Hôpital Salengro, Lille

75013

Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Paris

75019

Hôpital de la Fondation Adolphe de Rothschild, Paris

Sponsors

Lead Sponsor

AlzProtect SAS
All Listed Sponsors
lead

AlzProtect SAS

INDUSTRY

NCT04008355 - A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP | Biotech Hunter | Biotech Hunter